Early Phase Medical Affairs Strategic Planning

Pharmaceutical and device companies, particularly those innovating and paving their way to scientific leadership, realize that Medical Affairs can be a strategic function for scientific engagement early in drug development and throughout commercialization.

Medical Affairs can gather insights to identify clinically meaningful differentiators by engaging with the external community years ahead of launch. These insights can inform clinical strategy and a holistic evidence generation plan to produce and enhance value substantiation. That external input is vital in assessing whether and how to progress the development process for a given project.

At the upcoming Early Phase Medical Affairs Strategic Planning Summit, you have the unique opportunity to hear from other industry colleagues and how they are strategically evolving the medical's role in early development by collecting and channeling information on the patient experience back to the R and D organization, turning patient data into actionable insights. In addition, participants have the opportunity to learn from our distinguished speaking faculty and network with other attendees, which combined will provide an excellent opportunity to gain new insights on how Medical Affairs can and should play a central role as the facilitator that brings the scientific voice to guide the design and execution of clinical studies.

TOP REASONS TO ATTEND:
1- Understanding the Value of Real-World Evidence Throughout the Development Stages to Support a Product's Value
2- Developing a Unique KOL Early Engagement Plan to Provide your Product a Critical Competitive Edge
3- Involving a Qualified Medical Affairs Team from the Start to Execute a Designed Strategy and Achieve Medical Affairs Goals
4- Implement a Well-Planned Strategy to Recruit, Engage and Manage your Medical Affairs Team Effectively.
5- Improving Collaboration with R and D to Become a More Strategic Medical Affairs Partner